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Objective: The utilization of endovascular abdominal aortic aneurysm repair (EVAR) in suitable patients has resulted in
decreased perioperative morbidity and mortality. Octogenarians as a subgroup have been more readily offered EVAR, as
it is less invasive, and therefore presumably better tolerated than conventional open aortic repair. The purpose of this
study is to investigate periprocedural and late EVAR outcomes in octogenarians compared with patients less than 80 years
of age.
Methods: From January 2003 to May 2008, 322 patients underwent EVAR. A total of 117 octogenarians were compared
with 205 patients less than 80 years of age. A retrospective review of the demographic data, aneurysm details,
perioperative morbidity, mortality, and late outcomes were analyzed.
Results: Octogenarians were significantly more likely to have a history of diabetes mellitus (51% vs 23%; P < .001),
coronary artery disease (45% vs 32%; P  .0165), chronic obstructive pulmonary disease (44% vs 30%; P  .0113), and
renal insufficiency (57% vs 31%; P< .0001). There were no significant differences in the rates of perioperative myocardial
infarction, stroke, death, intestinal, or arterial ischemic complications between the two groups. Octogenarians had a
significant higher rate of pulmonary complications (5.1% vs 1%; P < .03) and access-site hematomas (12% vs 2.4%; P 
.001) than younger patients. When all significant perioperative morbidity was combined, octogenarians were twice as
likely to develop complications following EVAR than younger patients (27.4% vs 11.7%; P .001). At 5-year follow-up,
younger patients were twice as likely to develop type II endoleaks.
Conclusions: EVAR can be performed safely and effectively in octogenarians, and the incidence of major complications
including myocardial infarction, stroke, and death is unchanged compared with younger patients. However, there is a
significantly increased rate of access-site hematomas, pulmonary, and perioperative complications in octogenarians as a
whole. Our findings suggest EVAR remains a suitable form of therapy in the elderly group provided there is an
appropriate preoperative evaluation and perioperative monitoring following repair. ( J Vasc Surg 2010;52:556-61.)Innovations in endovascular techniques to treat vascu-
lar disease have helped reshape the landscape of vascular
surgery as we enter the twenty-first century. Arguably, the
most important paradigm shift has been the rapid adoption
of endovascular repair of abdominal aortic aneurysm
(EVAR). Ever since Parodi deployed the first endoluminal
aortic stent graft in Argentina in 1991, there has been a
widespread use of this technique.1 Patients who at one time
would have been considered poor candidates for open
abdominal aortic aneurysm (AAA) repair due to advanced
age or medical comorbidities have increasingly been treated
by EVAR.2 At least one prospective randomized trial has
reported that EVAR yields less blood loss, a shorter length
of stay (LOS), and a lower prevalence of postoperative
patient transfer to rehabilitation facility.3 Both patients and
referring physicians have been more accepting of this less-
obtrusive intervention. As such, octogenarians as a sub-
group have been more readily offered EVAR over tradi-
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556tional open repair as it is less invasive and therefore
presumably better tolerated than conventional open aortic
repair.4 Nevertheless, a recent European randomized trial,
EVAR 2, has examined the efficacy and safety of EVAR in a
high-risk cohort and concluded that EVAR may offer no
particular advantage over its untreated cohort.5
There has been a scarcity of long-term outcome studies
on EVAR in the octogenarian population in North Amer-
ica.6 The purpose of this study is to investigate our peripro-
cedural and late EVAR outcomes in octogenarians com-
pared with patients less than 80 years of age.
METHODS
Patients treated and followed at New York University
Medical center from the years 2003 to 2008 were analyzed.
A total of 322 patients underwent elective endovascular
repair of abdominal aneurysms; 205 were less than 80 years
of age, while 117 were octogenarians. Bifurcated, modular
endografts with two docking limbs and aortouniiliac de-
vices were considered for this study. Patients undergoing
reoperative endografting following prior EVAR or open
aneurysm repair were excluded. Devices implanted included
198 Zenith (Cook, Bloomington, Ind), 70 Excluder (W.L.
Gore & Associates, Flagstaff, Ariz), 47 AneuRx (Medtronic,
Santa Rosa, Calif), 5 Aptus (Endosystems, Sunnyvale, Calif),
and 2Renu (Cook, Bloomington, Ind). Patients were primar-
ily identified using ICD-9 coding system for EVAR repair
(39.71) and coding for endoprosthesis deployment
(34802, 34803). Once our internal database was queried,
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 3 Fonseca et al 557hospital and office charts were retrospectively reviewed.
Information collected included demographic data, aneu-
rysm details, comorbidities, perioperative morbidity and
mortality, and late outcomes. Postprocedural follow-up
adhered to a strict surveillance protocol that included a
clinical examination as well as helical computed tomogra-
phy (CT) angiogram at 1 month and at least every 12
months thereafter. Patients with chronic renal insufficiency
were followed by yearly CT of the abdomen without iodin-
ated contrast or abdominal ultrasound performed at our
institution ICAVL vascular laboratory. Aortic sac size in-
crease prompted further investigation via an aortogram.
The primary outcome measures of aneurysm repair
were: (1) perioperative mortality, defined as death occur-
ring within 30 days of EVAR; (2) early and late aneurysm-
related mortality; and (3) nonaneurysm-related mortality
up to 5 years. Secondary outcome measures included sig-
nificant perioperative complications following EVAR for a
period of 30 days. Perioperative complications assayed in-
cluded myocardial infarction (MI), stroke, intestinal isch-
emia, arterial ischemia, renal insufficiency, pulmonary
complications, and access-site hematoma. Pulmonary com-
plications were defined as bronchopulmonary infections
diagnosed from sputum culture or radiography, necessitat-
ing antibiotic therapy. Prolonged ventilatory assistance sec-
ondary to pulmonary infections or chronic obstructive pul-
monary disease (COPD) exacerbation were also classified as
pulmonary morbidity. Access-site hematomas included
those identified during clinical rounds and confirmed by
either duplex ultrasound or CT. Renal insufficiency was
defined as a decrease in glomerular filtration rate (GFR) to
60 mL/min/1.73 m2. GFR monitoring occurred in the
first postoperative laboratory and trended during the entire
hospitalization. The diagnosis of postprocedural renal in-
sufficiency required at least three separate GFR values.
Statistical analysis. Statistical analysis was performed
using SPSS statistical software (SPSS 16.0, Chicago, Ill).
Categorical variables were compared using 2 analysis, or
the Fisher exact test when appropriate. Survival analysis was
performed using the Kaplan-Meier method, with compar-
isons between groups performed using log-rank analysis. A
result was considered statistically significant with a P value
of .05.
RESULTS
Demographics. Patient demographics were com-
pared between octogenarians and younger patients. Octo-
genarians were more likely to be female (26.5% vs 12%; P
.006) and were significantly more likely to have a history of
diabetes mellitus, coronary artery disease, hypertension,
COPD, and renal insufficiency (Table I). The mean length
of stay was significantly longer among octogenarians un-
dergoing EVAR than younger patients (4.7 days vs 2.9
days; P  .02).
Surgical factors and perioperative outcome. As seen
in Table II, Zenith (Cook, Bloomington, Ind) grafts were
the most commonly implanted grafts at our institution.
There was no significant difference between graft type andage group (P  NS). Perioperative outcomes were com-
pared between octogenarians and younger patients. There
were no significant differences noted in the rates of periop-
erative MI, stroke, death, intestinal, or arterial ischemic
complications between the two patient groups (Table III).
However, octogenarians had a significantly higher rate of
pulmonary complications (5.1% vs 1%, P .03) and access-
site hematomas (12% vs 2.4%, P  .001) than younger
patients; however, none of these complications were life
threatening (Table III). Despite a higher rate of access-site
hematomas in octogenarians, only 21% required transfu-
Table I. Patient demographic data, risk factors and
comorbidity
Variables
Age  80
(n  205)
Age  80
(n  117) P value
Males, No. (%) 88% (182) 73.5% (86) .006
Age, mean  SD 71 ( 6) 85 ( 3.5) —
Tobacco, No. (%) 13.6 (28) 18.8 (22) .26
Aneurysm size
 SD 5.8 cm ( 1.3) 5.8 cm ( 1.3) .5
CAD, No. (%) 31.7 (65) 45.2 (53) .165
DM, No. (%) 23 (47) 51 (60) .0001
HTN, No. (%) 51 (105) 79 (92) .0001
COPD, No. (%) 30 (62) 44 (52) .0113
Renal, No. (%) 30.7 (63) 57 (67) .0001
ASA  3, No. (%) 13.6 (28) 24.8 (29) .0150
ASA, American Society of Anesthesiologists scale; CAD, coronary artery
disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mel-
litus; HTN, hypertension.
Table II. Endograft distribution
Endografts
Age  80
(n  205)
Age  80
(n  117) P value
Zenith (%) 63% (129) 59% (69) NS
Excluder (%) 20% (42) 24% (28) NS
AneuRx (%) 15% (31) 14% (16) NS
Aptus (%) 0.5% (1) 3.4% (4) NS
Renu (%) 1% (2) (0) NS
Zenith & Renu (Cook, Bloomington, Ind); Excluder (W.L. Gore & Asso-
ciates, Flagstaff, Ariz); AneuRx (Medtronic, Santa Rosa, Calif); Aptus (En-
dosystems, Sunnyvale, Calif).
Table III. Thirty day perioperative outcome
Morbidity
 80 years
(N  205)
Octogenarian
(N  117) P value
Myocardial infarction 1.5% (3) 1.7% (2) NS
Stroke .5% (1) 1.7% (2) NS
Intestinal ischemia 0.5% (1) 1.7% (2) NS
Arterial ischemia 2% (4) .9% (1) NS
Renal 3.9% (8) 6% (7) NS
Pulmonary 1% (2) 5.1% (6) P  .03
Access-site hematoma 2.4% (5) 12% (14) P  .001
All complications 27.4% 11.7% P  .001
Early death (30 days) 0.5% (1) 1% (1) NSsion of PRBC, and neither cohort required operative inter-
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sis of gender in patients who developed access-site
hematomas reveals no difference between either males or
females (5.2% vs 9.3%; P  .336).
Octogenarians had a higher incidence of postoperative
renal insufficiency than younger patients (6.0% vs 3.9%; P
.4), although this was not statistically significant. When all
significant perioperative morbidity was combined, octoge-
narians were more likely to develop any significant periop-
erative complication following EVAR than younger pa-
tients (27.4% vs 11.7%; P  .001). Surprisingly, we found
no statistical difference in the perioperative (30 days) all-
cause mortality (Table III).
Late follow-up. During late follow-up, we evaluated
both cohorts for endoleaks, aneurysm-related mortality,
and any-cause mortality. Unexpectedly, as seen on Table IV,
during late follow-up, elderly patients had a statistically
lower rate of overall endoleaks compared with younger
patients (21.4% vs 10%, P  .01). Nevertheless, there was
no difference in endoleaks requiring intervention in neither
age group (3.4% vs 4.3%, P  NS). Five-year survival was
calculated using the Kaplan-Meier method. Five-year over-
all survival for octogenarians was 95%, compared with 96%
for younger patients (see Fig). There was no significant
difference in late survival between the two patient groups
(Table V). Aneurysm-related death was also not signifi-
cantly different in older patients compared with younger
patients (Table V).
DISCUSSION
AAA repair bears a significant clinical and epidemio-
logic challenge to vascular surgeons and endovascular spe-
cialists. AAA is an age-related disease.7 The past 10 years
have seen an annual rise of more than 160,000 octogenar-
ians in the United States, and some estimates predict this
population will rise nearly fivefold by 2040.8 Accordingly,
it is expected that the rate of elective AAA repair and
aneurysm-related mortality due to rupture would also in-
crease. In fact, Giles et al report the annual number of AAA
repairs in the post-EVAR era has increased, as well as the
proportion of octogenarian patients treated.9 As the popu-
lation ages, it becomes imperative that the results of EVAR
in the octogenarian population are optimized. Asymptom-
atic AAA repair remains an elective, prophylactic procedure
with the hope of maximizing years of life while minimiz-
ing morbidity and mortality of the surgery.3
As expected, our group of octogenarians had a statisti-
Table IV. Endoleaks follow-up (5 years)
 80 years  80 years P value
All endoleaks 25 (21.4%) 21 (10%) .01
Type I endoleaks 3 (2.6%) 2 (0.9%) NS
Type II endoleaks 22 (18.8%) 19 (9.3%) 0.01
Endoleaks requiring
intervention 5 (4.3%) 7 (3.4%) NScally higher rate of comorbidities compared with youngerpatients. Along the same lines as EUROSTAR,10 the larg-
est European registry analyzing EVAR outcomes in octo-
genarians, our cohort of elderly patients had a higher rate of
CAD (P  .0165), COPD (P  .0113) and preoperative
renal insufficiency (P  .001). The unfavorable risk profile
of octogenarians was also reflected in a higher ASA  3
classification than the younger group (P  .0150). Inevi-
tably, elderly patients in our study had somewhat higher
Fig. Kaplan-Meier graph represents long-term survival after endo-
vascular repair of abdominal aortic aneurysms in octogenarians and
patients aged 80 years. Solid line  Less than 80 years; Dashed
line  Octogenarians.
Results of Kaplan-Meier analysis
Months following EVAR
1 12 36 60
At risk
Octogenarian (N  91) 90 88 78 65
Nonoctogenarian (N  205) 204 201 132 41
Survival (%)
Octogenarian 98.9 96.7 93.0 91.6
Nonoctogenarian 99.5 99.5 95.0 90.5
Standard error
Octogenarian 1.1 1.9 2.8 3.0
Nonoctogenarian 0.5 0.5 1.9 3.6
There is no significant difference in survival between octogenarians and
nonoctogenarians (P  .76 by log-rank [Mantel-Cox] analysis).
Table V. Late outcome: mortality
Outcome
 80 years
(N  205)
Octogenarian
(N  117) P value
Nonaneurysm-related
death (5 years) 10% (20) 8% (9) NS
Aneurysm-related
death (5 years) 1% (2) 1% (1) NS
Total deaths 10% (22) 9% (10) NScomplication rates post-EVAR. Similar to EUROSTAR,
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narians were found more likely to develop all-cause com-
plications than younger patients (27.4% vs 11.7%, P 
.001). In our 30-day mortality outcome, the only death
seen in the elderly group was a case of intestinal ischemia in
a patient with a previous history of colectomy, who subse-
quently developed multiorgan failure. This was surprising,
given the increased rate of preoperative comorbidities in
the older cohort.
At 30 days, octogenarians were five times as likely to
develop a pulmonary complication (5.1% vs 1%; P  .3).
Perioperative pulmonary complications ranged from un-
complicated pneumonia treated with oral antibiotics, to
more serious COPD exacerbation requiring prolonged
ventilatory assistance, and home oxygen therapy. This rate
of pulmonary complications in our elderly cohort may have
been exacerbated by two factors. Despite medical optimi-
zation, most octogenarians had preexisting COPD, which
contributed to these results. In addition, the overwhelming
majority of both groups were anesthetized using endotra-
cheal intubation. Octogenarians also experienced a higher
rate of access-site hematomas (P  .001); this may be
related to a more significant degree of calcific atheroscle-
rotic disease in the femoral arteries of older patients, or to a
difference in antiplatelet regimens. To exclude the possibil-
ity that octogenarians had a higher rate of access-site hema-
tomas due to female gender and smaller vessels, a subanaly-
sis was carried. As a whole, female gender proved no
difference in either age cohort.
Interestingly, the perioperative rate of renal compli-
cation was the same in both age groups, despite a higher
proportion of pre-existing renal dysfunction in octoge-
narians. Octogenarians in our series experienced only a
trend toward higher postoperative renal insufficiency
than younger patients (6.0% vs 3.9%, P  .4). This is
particularly significant when considering acute renal fail-
ure is a known complication of EVAR, with rates ranging
from 4% to 9%.11-13 We believe this is explained by a
strict adherence to renal prophylaxis guidelines with
intravenous hydration and acetylcysteine for patients
with baseline GFR under 60 mL/min.14,15
Our late outcomes support the notion that EVAR is a
safe method of treating elderly patients with AAAs that
provides successful protection against aneurysm-related
death. Historically, elective open repair in octogenarians
have yielded higher mortality rates.16 The natural history of
AAA rupture in sick and elderly patients has been eluci-
dated by Conway et al.17 His team followed 106 patients
deemed unfit for open AAA repair. The rupture rates at 3
years were 36% for AAAs 5.5 to 5.9 cm and 50% for AAAs
greater than 6 cm. Given his conclusions, watchful obser-
vance of patients with AAAs deemed unfit for open repair
should only be applied as a last resort. According to several
multicenter, controlled investigational device exemption
trials, the 4-year AAA-relatedmortality in high-risk patients
after EVAR is only 4%.18-20 In our study, we found the
aneurysm-related death at 5 years for elderly patients was 1%
(P  NS). Surprisingly, this was not statistically differentfrom the younger cohort. Furthermore, all-cause mortality
at 5 years was actually smaller in the octogenarian group
compared to younger patients (8% vs 10%; P  NS). One
explanation for this finding may be one of selection bias,
that our team inadvertently selected a very robust set of
octogenarians for EVAR. Another unexpected finding was
the overall endoleak rate and type II endoleaks were less
common in octogenarians than the younger group (Table
IV). In contrast to the healthier cohort, octogenarians
experienced the same rate of endoleaks requiring interven-
tion (3.4% vs 4.3%; PNS).We reported that theremay be
an increase in the rate of type I endoleak in patients with
more difficult anatomy.21 This is especially true for patients
deemedmedically unfit for open aneurysm repair whom are
then treated with endografts despite poor anatomic condi-
tions as an alternative to “watchful waiting”. However, in
the current series, the overall increased rate of endoleak was
secondary to an increased rate of type II leaks in our elderly
cohort. The explanation for this finding remains elusive.
There are several limitations to our study. As described
above, the recruitment of data in this study may predispose
toward selection bias. We may have inadvertently selected
for a very healthy group of octogenarians, or may have
selected for a particularly sick group of younger patients
who might not tolerate open repair. Second, our sample
size was small, therefore making statistical analysis prone to
error. And, lastly, the retrospective nature of the data
review is a suboptimal method of determining trends.
CONCLUSION
EVAR can be performed safely and effectively in octo-
genarians, and the incidence ofmajor complications includ-
ing MI, stroke, and death is not increased compared with a
younger patient cohort. However, there is a significantly
increased rate of pulmonary complications and access-site
hematomas noted in octogenarians, as well as perioperative
complications as a whole. Slightly more than 25% of octo-
genarians who underwent EVAR in this study experienced
some sort of perioperative complication, and this likely
resulted in the overall increased length of stay in the older
age cohort. Although EVAR is certainly appropriate in
octogenarians, clinicians should be particularly mindful of
appropriate preoperative evaluation and perioperative
monitoring to minimize the risk of such postoperative
events.
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Dr Thomas Forbes (London, Ontario, Canada). With the
absence of long-term outcomes in octogenarians, the authors set
out to investigate periprocedural and long-term outcomes in these
patients compared to younger patients. Over a recent 5-year pe-
riod, they treated 320 patients, a third of which were over 80 years
of age. Not only were these patients older, but they were also
sicker, with higher degrees of coronary disease, diabetes, hyperten-
sion, COPD, and renal dysfunction.
Their 5-year outcomes were reassuring in that these patients
had similar survival compared with younger patients. From the
data presented, I am not sure what proportion of them actually had
5-year follow-up completed, given that this study took place
between 2003 and 2008. However, these results are reassuring
that these older patients appear to have sufficient life expectancy to
benefit from the prophylactic nature of elective aneurysm repair.
I have several specific questions regarding these findings. The
authors observed an early increased rate of pulmonary complica-
tions and access-site hematomas in these older patients. Could the
pulmonary complication rate be due to the use of general anesthe-
sia? If so, these older patients might benefit from the use of
regional anesthesia techniques that might limit these pulmonary
complications and length of stay.
The authors observed an increased rate of groin hematomas in
these elderly patients. This is an interesting finding. Is this a factor
of antiplatelet medication, or some technical factor? As well, why
do the authors suppose that octogenarians were more apt to have
a type II endoleak? Is this a true observation, or a factor of differing
surveillance regimens?
Dr Fonseca. As to your first question, this is pretty much in
line with EUROSTAR data, that they have looked at their periop-to have high rates of access-site hematomas, pulmonary complica-
tions. Yet, in contrast to our study, they also found worsening renal
dysfunction in the elderly population.
When analyzing our pulmonary complications in elderly pa-
tients, our institution, for the most part, uses endotracheal intuba-
tion and general anesthesia, unless there is a prohibitive risk. So
certainly those patients that had such a significantly reduced FEV1
usually undergo EVAR under spinal and regional anesthesia, but
we usually try to institute general anesthesia to ensure better
precise deployment of endografting.
In terms of access-site hematomas, we have been looking at
this and we are actually doing a retrospective analysis specifically
looking at the mode and the type of either mono or dual antiplate-
let regimen that some of those patients might have had, especially
some of the sicker, elderly patients with more extensive preopera-
tive coronary artery disease. Right now, we are still in the process of
gathering these data, but we suspect that the amount of antiplatelet
agents has something to do with it.
Something else that can explain this, although speculative, as
you become elderly, your vessels are somewhat more calcific and
might have contributed to access-site hematomas. But of all the
hematomas that were reviewed in our literature, only three of those
patients had to be taken back to the operating room for decom-
pression and washout. So that was significant.
In terms of type II endoleaks, I completely agree with you. We
are perplexed by these data. The only thing that comes to mind is
perhaps these octogenarians, and we have to basically look back at
the post-EVAR aortogram, but we suspect that perhaps these
patients have a lesser rich amount of collaterals and lumbar arteries
that are not contributing to as much as type II endoleaks. But
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elderly and younger patient cohorts were the same.
Dr David Neschis (Baltimore, Md). I have a comment to
further support your results. As you might recall, in EVAR-2, a
substantial number of patients in the repair group, in waiting to getcounted as operative deaths. In the same vein, I think it was about
27% of patients who were in the surveillance group decided they
did not want to sit around and wait until they burst. I believe they
left the study, got treated, and those patients had a 2% mortality,
not the 9% reported for the repair group. So I think your findingstheir repair, ruptured before the repair occurred. Those were are consistent and should support policy.
